Activities
Plan and share activities for IYC 2011
Want to submit your own activity or comment?
In order to do so you need to be part of the IYC network. Please log in or sign up now.
Join the IYC Network
In this section, your ideas for IYC2011 can start to become reality. Here, you can submit activities for consideration and, after a short review, they will be listed below and any related events will populate the IYC calendar. Activities listed here have a clearly defined theme and describe how, when, and where they will take place.
If you are not quite ready to submit a plan, keep working at it and come back soon. And remember, you can always browse and search this forum to find out what others are planning and even add your own comments to the discussion.
Currently viewing all activities tagged with educators in audiences - See all activities
Designing safer medicines in discovery: current and emerging opportunities Jacqui Colgate | added on Nov 18, 2010 | United Kingdom This meeting will look at how better Clinical Candidates can be designed with an enhanced awareness of potential future safety issues.
Hurter Lecture Jacqui Colgate | added on Nov 18, 2010 | United Kingdom Hurter Lecture
Family Evening Lecture: Copies, Fakes and Forgeries: Analysis in the study of art and Antiques Jacqui Colgate | added on Nov 18, 2010 | United Kingdom Family Evening Lecture: Copies, Fakes and Forgeries: Analysis in the study of art and Antiques
Family Evening Lecture: Mercury Window on the Invisible Jacqui Colgate | added on Nov 18, 2010 | United Kingdom Mercury is the most beautiful element in the periodic table. And the most reviled. The only liquid metal, its inertness and density have made it crucial to a huge number of experiments through history. Dr Andrea Sella, will take us on a tour of Mercury-related science and will end with the question can we bring it to life?
Opportunities for commercialising drug discovery in the academic sector Jacqui Colgate | added on Nov 18, 2010 | United Kingdom Converting early stage research into commercially valuable drug discovery assets

